Here is the design of a clinical trial:

Official Title: Relieving Acute Pain (RAP): A Pilot Study

Included conditions:
- Trauma
- Opioid Use
- Spine Fusion

Study Armgroups:
- {'label': 'Full Dose (FD)', 'type': 'ACTIVE_COMPARATOR', 'description': 'Participants in the FD arm will receive NSAIDs and Oxycodone (5mg).dosed in accordance with the Guidelines for Use from University of Maryland Shock Trauma Center.', 'interventionNames': ['Drug: Oxycodone', 'Drug: Ketorolac']}
- {'label': 'PR (Partial Reinforcement)', 'type': 'PLACEBO_COMPARATOR', 'description': 'Participants in this group will receive NSAIDs, Oxycodone (5mg), and placebo pills to reach a 50% reduction of the total intake of opioids.', 'interventionNames': ['Drug: Oxycodone', 'Drug: Ketorolac', 'Other: Placebo']}
- {'label': 'C (Control)', 'type': 'PLACEBO_COMPARATOR', 'description': 'Participants in this group will receive NSAIDs and placebo pills', 'interventionNames': ['Drug: Ketorolac', 'Other: Placebo']}

Interventions:
- {'type': 'DRUG', 'name': 'Oxycodone', 'description': '5mg Oxycodone in oral solution given every 3 hours', 'armGroupLabels': ['Full Dose (FD)', 'PR (Partial Reinforcement)'], 'otherNames': ['Oxycodone Hydrochloride']}
- {'type': 'DRUG', 'name': 'Ketorolac', 'description': 'toradol intravenous (IV) 30mg. Maintain toradol IV every 8 hours, round the clock. For patients with renal insufficiency, decrease toradol dose to 15mg every 8 hours. For patients over 65 years old, decrease toradol dose to 15 mg every 8 hours. After 24 hours, start oral NSAIDS every 8 hours round the clock when tolerating pain.', 'armGroupLabels': ['C (Control)', 'Full Dose (FD)', 'PR (Partial Reinforcement)'], 'otherNames': ['Toradol']}
- {'type': 'OTHER', 'name': 'Placebo', 'description': 'Oral solutions containing only the carrier vehicle - a flavored syrup called OraSweet', 'armGroupLabels': ['C (Control)', 'PR (Partial Reinforcement)'], 'otherNames': ['OraSweet']}

Primary Outcomes:
- {'measure': 'Pain Self-reports', 'description': 'Collected on a visual analogue scale, with 0 being "no pain" and 100 being "maximum pain tolerable"', 'timeFrame': 'Day 1-7, Week 2, Months 1, 3 and 6'}

Please estimate the sample size based on the assumption: 
Alpha set at 0.05, F equal to 3.054, and account for 20% participant withdrawal.
Sample size calculation
        This study will enrol a total of 159 participants with 53 participants assigned to each of the three arms. We predict in the FD group that patients will take a maximum of 90âmg (5âmg every 4âhours for 3âdays) and in PR group that patients will take a maximum dose of 45âmg (5âmg every 4âhours for the first 24âhours and then estimated every 6âhours for 2âdays) with an overall reduction of opioids in the hospitalisation window of approximately 50%. We expect a small change in pain report (0.25%), and account for 20% participant withdrawal. Therefore, we will need to recruit 159 participants, with 53 participants per group, to achieve a significant difference across groups (alpha set at 0.05 and F equal to 3.054).